Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

SeraCare Life Sciences Unveils Suite Of Products In Genetic Controls Portfolio

SeraCare Life Sciences, Inc. (SeraCare Life Sciences) has unveiled a new suite of products in its genetic controls portfolio to support cystic fibrosis genetic research. The controls, ACCURUN 632, 644 and 676, are the single-vial products that control for testing of all cystic fibrosis mutations detected by testing platforms, the company.

Cystic fibrosis is a devastating hereditary chronic disease typically diagnosed in children before the age of two and is marked by mucus build-up and clogging of key organs in the body, especially the lungs and pancreas.

SeraCare serves the global life sciences industry by providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics.